The Role of Neutrophil Gelatinase-Associated Lipocalin and N-Terminal Pro B-Type Natriuretic Peptide in the Prediction of Heart Failure in Patients with Acute Coronary Syndrome

BACKGROUND: Heart failure, where the heart cannot pump blood effectively, significantly affects patient quality of life and impacts national health-care services. Acute coronary syndrome is a common underlying cause of acute heart failure. Neutrophil gelatinase-binding lipocalin (NGAL) and N-termina...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open access Macedonian journal of medical sciences 2022-12, Vol.10 (B), p.2566-2572
Hauptverfasser: Tran, An Viet, Tran, Nguyet To, Nguyen, Khue Duy, Huynh, An Tuan, Nguyen, Diem Thi, Nguyen, Khuong Duy, Nguyen, Thang, Tran, Van De, Dewey, Rebecca Susan
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND: Heart failure, where the heart cannot pump blood effectively, significantly affects patient quality of life and impacts national health-care services. Acute coronary syndrome is a common underlying cause of acute heart failure. Neutrophil gelatinase-binding lipocalin (NGAL) and N-terminal pro B-type natriuretic peptide (NT-proBNP) are biomarkers released during myocardial injury. Thus, the measured levels of these chemicals may be associated with heart failure events in patients with acute coronary syndrome. AIM: The present study determined the serum levels and measured increases in NGAL and NT-proBNP, as well as recorded heart failure events in patients with acute coronary syndrome in Vietnam. METHODS: A descriptive cross-sectional method was used to recruit 58 patients with acute coronary syndrome and assess the degree to which the two markers could predict ejection fraction (EF). RESULTS: The median values of NGAL and NT-proBNP concentrations in the group with EF ≥40% (7.14 ng/mL and 952.00 pg/mL) were significantly lower than those with EF
ISSN:1857-9655
1857-9655
DOI:10.3889/oamjms.2022.10897